Hailir’s key product prothioconazole, with 2,000 tons capacity, officially entered trial production stage

Hailir announced on September 28, 2020 that the trial production plan of 2,000 tons prothioconazole fungicide technical, invested and constructed by its wholly-owned subsidiary Shandong Hailir, met the trial production conditions after expert review and passed the review, and officially entered the trial production stage.

Prothioconazole has the good characteristics of disease prevention and treatment effects, obviously yield increase, and broad-spectrum bactericidal activity. It has a broad market prospect. The production of prothioconazole technical will bring new profit growth points to Hailir and become a new engine for its high-quality development, which will help further consolidate, enhance and optimize its core competitiveness, and have a positive impact on the continuous growth of the company's future performance.

It is understood that Hailir is actively planning to add the second projects for 20,000 tons of prothioconazole’s key intermediate and 5,000 tons of prothioconazole technical production capacity.